血清尿酸水平作为慢性阻塞性肺疾病的生物标志物：一项荟萃分析。

Serum uric acid level as a biomarker for chronic obstructive pulmonary disease: a meta-analysis.

机构信息

Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.

出版信息

J Int Med Res. 2021 Jan;49(1):300060520983705. doi: 10.1177/0300060520983705.

DOI:10.1177/0300060520983705

PMID:33459103

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816533/

Abstract

OBJECTIVE

To determine if there is a relationship between the levels of serum uric acid and the different Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (1-4) classified by the severity of the airflow limitation in patients with stable chronic obstructive pulmonary disease (COPD).

METHODS

Electronic databases, including PubMed®, Embase®, Web of Science™ and China National Knowledge Infrastructure (CNKI), were searched from inception to December 2018. Observational studies that reported serum uric acid levels in stable COPD patients were included. Two investigators independently extracted data and RevMan version 5.3 was used to carry out the statistical analyses.

RESULTS

Seven studies with 932 stable COPD patients and 401 healthy control subjects were included in this meta-analysis. Serum uric acid levels were significantly higher in stable COPD patients compared with healthy control subjects (mean difference [MD] 1.91, 95% confidence interval [CI] 1.55, 2.28). Serum uric acid levels were significantly lower in the GOLD 1+2 subgroup compared with the GOLD 3+4 subgroup (MD -1.39, 95% CI -1.63, -1.15).

CONCLUSION

Serum uric acid might be a useful biomarker for identifying disease severity in stable COPD patients, but further studies are needed to confirm this finding.

摘要

目的

确定血清尿酸水平与慢性阻塞性肺疾病（COPD）稳定患者气流受限严重程度不同的全球倡议慢性阻塞性肺病（GOLD）分期（1-4 期）之间是否存在关联。

方法

检索了从创建到 2018 年 12 月的电子数据库，包括 PubMed®、Embase®、Web of Science™和中国国家知识基础设施（CNKI）。纳入了报告稳定 COPD 患者血清尿酸水平的观察性研究。两名研究者独立提取数据，使用 RevMan 版本 5.3 进行统计分析。

结果

本荟萃分析纳入了 7 项研究，共 932 例稳定 COPD 患者和 401 名健康对照者。与健康对照组相比，稳定 COPD 患者的血清尿酸水平明显升高（平均差值 [MD] 1.91，95%置信区间 [CI] 1.55，2.28）。GOLD 1+2 亚组的血清尿酸水平明显低于 GOLD 3+4 亚组（MD -1.39，95% CI -1.63，-1.15）。